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Abstract: The Massachusetts General Hospital Hairpulling Scale (MGH-HPS) 
and the NIMH Trichotillomania Severity Scale (NIMH-TSS) are two widely 
used measures of trichotillomania severity. Despite their popular use, 
currently no empirically-supported guidelines exist to determine the degrees 
of change on these scales that best indicate treatment response. 
Determination of such criteria could aid in clinical decision-making by defining 
clinically significant treatment response/recovery and producing accurate 
power analyses for use in clinical trials research. Adults with trichotillomania 
(N = 69) participated in a randomized controlled trial of psychotherapy and 
were assessed before and after treatment. Response status was measured via 
the Clinical Global Impressions-Improvement Scale, and remission status was 
measured via the Clinical Global Impressions-Severity Scale. For treatment 
response, a 45% reduction or 7-point raw score change on the MGH-HPS was 
the best indicator of clinically significant treatment response, and on the 
NIMH-TSS, a 30–40% reduction or 6-point raw score difference was most 
effective cutoff. For disorder remission, a 55–60% reduction or 7-point raw 
score change on the MGH-HPS was the best predictor, and on the NIMH-TSS, 
a 65% reduction or 6-point raw score change was the best indicator of 
disorder remission. Implications of these findings are discussed. 
 
Keywords: Hair pulling, Trichotillomania, Obsessive-compulsive disorder, 
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1. Introduction 
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Researchers have demonstrated the efficacy of various 
treatments for reducing hair pulling in adults with Trichotillomania 
(TTM; Bloch et al., 2007). Such studies typically utilize 
psychometrically-validated measures of pulling severity (Grant et al., 
2009, Keuthen et al., 2012 and Woods et al., 2006), the most 
common of which are the Massachusetts General Hospital Hairpulling 
Scale (MGH-HPS; Keuthen et al., 1995) and the National Institutes of 
Mental Health Trichotillomania Severity Scale (NIMH-TSS; Swedo et 
al., 1989). 
The MGH-HPS is a self-report measure and the NIMH-TSS is 
clinician-rated. Both are dimensional scales that possess sensitivity to 
change in TTM treatment studies (Diefenbach et al., 2005 and Swedo 
et al., 1989). Although existing treatments have yielded statistically 
significant changes in scores on both measures (Woods et al., 2006), 
the magnitude of reductions needed to signify clinically significant 
change is unclear. 
When no clear cutoffs exist for a primary outcome measure, 
establishing the clinical significance of change requires the 
incorporation of additional information. For instance, clinicians might 
rely on a combination of qualitative and quantitative data to gauge 
improvement, thereby interpreting scores based on clinical judgment. 
An example of this type of measurement is the Clinical Global 
Impressions Scale (CGI; Guy, 1976), which consists of a severity index 
(CGI-S) and treatment improvement index (CGI-I). The CGI is a 
clinician-rated measure that incorporates multiple sources of data and 
provides a clearly interpretable metric of holistic disorder severity and 
treatment response. The CGI is also widely used in clinical trials 
(Bandelow et al., 2006, Leon et al., 1993, Leucht and Engel, 2006, 
Leucht et al., 2005, Spielmans and McFall, 2006 and Zaider et al., 
2003) and has been used for trichotillomania (e.g., Keuthen et al., 
2011 and Keuthen et al., 2012). To best determine the level of 
symptom reduction as measured by popular assessments of hair 
pulling severity, one could measure the points at which score 
reductions on dimensional measures (i.e., MGH-HPS and NIMH-TSS) 
converge best with the thresholds of clinical significance on the CGI-I 
and CGI-S. 
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Developing guidelines for clinically significant change on the 
MGH-HPS and NIMH-TSS would have numerous benefits in both 
research and clinical practice. When designing a randomized controlled 
trial (RCT), one ensures that the study is adequately powered to 
detect the desired effect size (Cohen, 1988 and Kraemer and 
Thiemann, 1987). Recent recommendations by Kraemer and Kupfer 
(2006) suggest that the level of power needed in studies be based on 
the determination of clinically significant effects. The current study 
attempts to identify clinically significant cutoff criteria in commonly 
used TTM outcome measures, so that future studies can better 
approximate the power needed to identify clinically significant effects. 
These guidelines will also have clinical utility, as a clinically meaningful 
change score can give therapists a target for change and can indicate 
the point at which change has become significant. 
A recent study examined the ability of changes in the MGH-HPS 
and another clinician-rated measure of hair pulling severity, the 
Psychiatric Institute Trichotillomania Scale (PITS; Winchel et al., 1992) 
to predict various meaningful outcomes (Nelson et al., 2014). Various 
potential clinical predictors were used, including Jacobson and Truax’s 
(1991) clinically significant change criteria (i.e., 1.96 times the reliable 
change index plus a post-treatment score that was two standard 
deviations below the dysfunctional population mean), complete 
abstinence from pulling (defined as a score of 0 on MGH-HPS item 4), 
25% reduction on the MGH-HPS or PITS, and the recovery criterion 
alone (e.g., score of ≤9 on the MGH-HPS or ≤14 on the PITS). Post-
treatment abstinence from hair pulling and the MGH-HPS 25% 
reduction predicted several positive outcomes (i.e., decision to 
successfully end treatment at step 2 in the stepped-care clinical trial, 
treatment satisfaction, and quality of life at 3-month follow-up), but 
the Jacobson and Truax clinically significant change criteria on the 
MGH-HPS predicted only quality of life at 3-month follow-up. The 25% 
PITS reduction predicted no outcomes, whereas the PITS-based 
recovery criterion predicted decision to end treatment and the 
Jacobson and Truax clinically significant change criteria on the PITS 
predicted absence of TTM diagnosis at 3-month follow-up. As such, it 
appears that the ways of defining different clinical predictors leads to 
differential prediction of various indices of treatment response. 
However, no cutoff stands out as the most efficient indicator of 
treatment response. Determining more efficient cutoffs might be 
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achieved through approaches that are not constrained by rigid 
definitions of these cutoffs, such as by testing the validity and 
efficiency of numerous score reductions as they converge with well-
defined measures of clinically significant change (i.e., the CGI). 
Indeed, five studies have performed signal detection analyses to 
determine such cutoffs with related conditions, such as obsessive-
compulsive disorder and tic disorders. Investigators found that a 25% 
decrease on the Children’s Yale-Brown Obsessive-Compulsive Scale 
was most efficient at predicting treatment response in childhood OCD, 
as measured by the CGI-I and the Child Obsessive-Compulsive Impact 
Scale (Storch, Lewin, De Nadai, & Murphy, 2010), while others found 
between 30 and 35% reductions on the Yale-Brown Obsessive-
Compulsive Scale were most efficient in predicting adult OCD 
treatment response as measured by the CGI-I (Lewin et al., 
2011 and Tolin et al., 2005). Likewise, a 35% reduction or 6–7 point 
raw score decrease on the Yale Global Tic Severity Scale (YGTSS) was 
found to best predict treatment response in Tourette syndrome as 
measured by the CGI-I (Storch et al., 2011), whereas Jeon et al. 
(2013) found that a 25% reduction on the YGTSS optimally predicted 
positive response as measured by the CGI-I in both children and 
adults with tic disorders. Although these studies allow clinicians to 
accurately predict which clients demonstrate clinically significant 
treatment response, no studies have determined reductions on 
dimensional measures of obsessive-compulsive related disorders that 
optimally predict disorder recovery. As was done in the Nelson et al. 
study on measures of treatment response in TTM, researchers have 
argued that estimates of clinical significance should calculate the 
propensity of a treatment to facilitate a decrease in symptoms within 
clinical individuals to those resembling normative levels ( Jacobson & 
Truax, 1991). Thus, it would be useful to determine if certain levels of 
symptom reduction on dimensional scales correspond to both reliable 
change and recovery of normal functioning. 
The present study sought to replicate the methods of previous 
signal detection analyses in defining treatment response for adults 
with TTM using both the MGH-HPS and the NIMH-TSS. In order to 
determine clinically significant treatment response, we used the CGI-I 
as the criterion measure. Similarly, the CGI-S was used as the 
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criterion measure of TTM recovery. No a priori hypotheses were made 
with regard to optimal cutoff points on the measures analyzed. 
2. Method 
2.1. Participants 
Although 85 participants were randomized into the clinical trial, 
only those who completed treatment were included in the present 
study. Participants were 69 adults (62 females) diagnosed with TTM 
whose ages ranged from 18 to 61 (M = 35.86, SD = 13.05). The 
sample was 85.5% Caucasian, 11.6% African–American, and 2.9% 
“other.” Data were collected as part of a randomized controlled trial for 
psychotherapy for adults with TTM (Woods et al., in preparation). Both 
therapeutic conditions tested in the trial (i.e., Acceptance-Enhanced 
Behavior Therapy and psychoeducation plus supportive 
psychotherapy) are included in these analyses. Also, only participants 
who completed both the baseline and post-treatment assessments 
were included. At baseline, mean scores on the MGH-HPS and NIMH-
TSS were 16.99 (SD = 4.68, Range = 8–26) and 14.54 (SD = 3.72, 
Range = 6–21), respectively. 
Inclusion criteria were: (1) a current DSM-IV-TR diagnosis of 
TTM (2) an MGH-HPS score of >12, (3) a Wechsler Test of Adult 
Reading score of >85, (4) age 18–65, (5) English fluency, (6) able to 
maintain outpatient status, (7) no initiation or change in psychotropic 
medication status or dosage for eight weeks preceding participation or 
during the study, (8) not currently receiving psychotherapy for any 
condition, and (9) completed all 10 sessions of treatment. 
Exclusion criteria included: (1) diagnosis of bipolar disorder, 
psychotic disorder, substance dependence (except nicotine 
dependence), or pervasive developmental disorder, and (2) severe 
mood or anxiety problems with potential suicidality. In addition, 
individuals who endorsed ingesting their hair after pulling were eligible 
for participation only after they had received a physical exam from 
their primary care physician. 
2.2. Treatment 
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Participants were randomized to receive either Acceptance-
Enhanced Behavior Therapy (AEBT; n = 35) or psychoeducation and 
supportive psychotherapy (PST; n = 34) control. For a detailed 
description of AEBT therapeutic techniques, see Woods and Twohig 
(2008). The PST protocol was derived from Pinsker (1997). Inclusion 
criteria mandated that participants maintain a stable dose on any 
medications for the 8 weeks prior to and during the study. In total, 
29% were currently taking a psychotropic medication during the study, 
but only 2.9% were prescribed medication for TTM. Of the sample, 
21.7% were taking selective serotonin reuptake inhibitors, 7.2% were 
taking other antidepressants (e.g., tricyclics), 7.2% were taking 
psychostimulants, 2.9% benzodiazepines, 2.9% reported taking 
atypical neuroleptics, and 1 person (1.4%) was taking Hydroxyzine (an 
antihistamine) for anxiety. One-fifth of the total sample (20.3%) were 
taking only one medication, while 4.3% were taking two medications 
and 4.3% were taking three or four medications. 
2.3. Measures 
The Structured Clinical Interview for DSM-IV Axis-I Disorders, 
Patient Edition (SCID-P; First, Spitzer, Gibbon, & Williams, 1996) was 
used to screen for psychiatric comorbidities. Additionally, the 
Trichotillomania Diagnostic Interview (TDI; Rothbaum & Ninan, 1994) 
was employed for obtaining TTM diagnosis. 
The MGH-HPS has demonstrated adequate psychometric 
properties (Diefenbach et al., 2005, Keuthen et al., 
1995 and O'Sullivan et al., 1995). It consists of seven items that are 
scored on a 0–4 Likert scale, resulting in total scores ranging from 0 to 
28, with higher scores indicating greater hair pulling severity. The 
MGH-HPS was administered at baseline and post-treatment. 
The NIMH-TSS has demonstrated adequate psychometric 
properties in adults (Diefenbach et al., 2005 and Swedo et al., 1989). 
Interviewers using the NIMH-TSS ask questions about time spent 
pulling, resistance to urges, distress, and impairment, resulting in total 
scores that range from 0 to 25. The NIMH-TSS was also administered 
at baseline and post-treatment. 
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The CGI was developed to provide a brief, stand-alone measure 
of clinician-rated global treatment response and disorder severity in 
NIMH-sponsored clinical trials (Guy, 1976). The CGI has evidence of 
convergent validity on many symptom severity scales across many 
psychiatric conditions in both pharmacological and psychosocial 
treatment paradigms (Bandelow et al., 2006, Leon et al., 1993, Leucht 
and Engel, 2006, Leucht et al., 2005, Spielmans and McFall, 
2006 and Zaider et al., 2003) and has been used for TTM (e.g., 
Keuthen et al., 2011 and Keuthen et al., 2012). The CGI-I is a single-
item clinician-rated measure that assesses the overall improvement of 
a person’s condition throughout treatment on an 8-point Likert scale 
(Range = 1–8). Scores of 1 and 2 (very much improved and much 
improved) are indicators of treatment response while all greater scores 
indicate treatment non-response. Similarly, the CGI-S is a single-term 
clinician rated measure that assesses the overall severity of a person’s 
condition on an 8-point Likert scale (Range = 1–8). Scores of 1 and 2 
(normal, not at all ill and borderline ill) are indicators of no TTM 
diagnosis or mild TTM symptoms, while all greater scores indicate 
significant TTM symptoms. The CGI-I and CGI-S were administered at 
post-treatment. To ensure the validity of CGI ratings, masked 
independent evaluators were trained in CGI administration and met 
weekly with the Principal Investigator (D.W.W.) to discuss and review 
taped assessments. 
2.4. Procedure 
Adults with TTM were recruited to participate in a randomized 
controlled trial of psychotherapy for TTM via local newspaper ads, 
public transportation flyers, newsletter and website advertisements via 
the Trichotillomania Learning Center (www.trich.org), and clinic 
referrals at a TTM specialty clinic. 
Potential participants were screened by telephone. All callers to 
a TTM clinic were provided information about the study and screened 
for possible participation. If the participant appeared to be eligible and 
interested, he or she was scheduled for an initial clinic visit, during 
which consent was obtained and inclusion/exclusion criteria checked. 
Participants deemed ineligible or those not wishing to participate were 
referred for standard clinical services. Potential participants (N = 274) 
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were screened via telephone. The baseline sample consisted of 91 
persons, of which 85 were randomized and 16 participants were lost 
throughout treatment, resulting in a post-treatment sample of 69 
persons. For additional details regarding screening, exclusions, and 
attrition, see Woods et al. (in preparation). Additionally, all clinician-
rated instruments were administered by masters- and doctoral-level 
independent evaluators who were masked to treatment condition. The 
CGI scales and the NIMH-TSS are rated using a semi-structured 
procedure. 
IRB approval for this project was obtained at Texas A&M 
University (IRB2013-3025) and the University of Wisconsin-Milwaukee 
(IRB09.039). The study is publicly listed on ClinicalTrials.gov 
(#NCT00872742), and was performed in compliance with the Code of 
Ethics of the World Medical Association (Declaration of Helsinki). 
2.5. Analyses 
The goal of the current study was to find the levels of symptom 
reduction needed on the MGH-HPS and NIMH-TSS that most optimally 
predicted treatment response (i.e., CGI-I < 3) and disorder recovery 
(i.e., CGI-S < 3). Both percent reductions and raw score reductions 
(from baseline to post-treatment) on each measure were used to 
predict the CGI-I and CGI-S. The authors chose not to define clinically 
significant treatment response as meeting both significant change on 
the CGI-I and significant recovery on the CGI-S. This decision was due 
to the fact that although many individuals with TTM wish to achieve 
complete abstinence from pulling, many others are satisfied with a 
significant reduction in hair pulling (Woods & Houghton, 2014). Thus, 
persons with severe TTM who show clinically meaningful symptom 
reductions but do not achieve complete recovery should not be 
discounted as having not responded to treatment, whereas those 
persons would be ignored by definitions of clinically significant 
treatment response that require both change and recovery. 
Additionally, performing such analyses separately allows a more 
detailed interpretation of the assessment of change in treatment for 
TTM. 
Receiver operating characteristic (ROC) methods (Swets & 
Pickett, 1982), which have been previously used for these purposes 
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(Storch et al., 2011), were used in the present study. ROC methods 
focus on the predictive validity of psychological tests, using statistics 
such as number of true positives, true negatives, false positives, and 
false negatives. In testing percent reduction cutoffs, we created cutoffs 
at every 5% interval between 5% and 70%. For raw scores, point 
reductions between 1 and 11 were evaluated. Following the 
methodology of Storch et al. (2011), our analysis operationalized score 
reductions as raters, then tested which reduction (or “rater”) has the 
best psychometric efficiency for detecting clinical response to 
treatment. 
ROC analyses incorporate several psychometric properties of 
assessments, including sensitivity, specificity, positive predictive 
power, negative predictive power, and efficiency. Sensitivity is defined 
as a measure’s ability to detect the presence of a given criterion (in 
this study, clinically significant treatment response or disorder 
recovery). Alternatively, specificity is defined as a test’s ability to 
detect the absence of a given criterion. Positive predictive power (PPP) 
reflects the proportion of correctly predicted positive results provided 
by a diagnostic test, whereas negative predictive power (NPP) reflects 
the proportion of correctly predicted negative results. Efficiency can be 
described as the accuracy of a test, such that a given cutoff or rating 
on a test “agrees” with another definitive test. 
Even the most psychometrically sound tests contain at least 
minimal measurement error (in this study, the CGI-I and CGI-S). 
Therefore, a weighted Kappa statistic was used to correct for such 
error when assessing the quality of efficiency (Kraemer, 
1992 and Kraemer et al., 2002). Weighted kappa statistics examine 
the agreement between measures but correct for measurement error 
in a manner similar to the method by which Cohen’s Kappa accounts 
for chance agreement in inter-observer reliability. For this analysis, the 
K(0.5) statistic was used, which ranges from 0.00–1.00. A value of 0 is 
indicative of agreement purely by chance, and a value of 1 reflects 
perfect classification (i.e., all true positives and true negatives). The 
K(0.5) statistic measures the quality of efficiency while weighing 
sensitivity and specificity equally, and was used in order to generalize 
results across contexts, following the approach of Storch et al. (2011). 
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3. Results 
3.1. Adequacy of measures for signal detection analysis 
Reliability analyses were performed in order to determine 
whether the MGH-HPS and NIMH-TSS were suitable for signal 
detection analysis. Test-retest reliability correlations were computed 
from the screening assessment date to the baseline assessment date, 
a time period that lasted, on average, 11.81 days (SD = 6.04). The 
MGH-HPS test-retest reliability coefficient was 0.45 (p < 0.001) and 
the NIMH-TSS reliability coefficient was 0.65 (p < 0.001), which are 
comparable to reliability coefficients of TTM severity instruments at 
similar intervals ( McGuire et al., 2012 and Stanley et al., 1993). 
Because these measures assess hair-pulling severity during the 
previous week, and because hair pulling is a constantly fluctuating 
behavior, we deemed these reliability coefficients to be acceptable and 
that the measures were suitable for signal detection analysis. 
3.2. Determining treatment response and recovery 
based on MGH-HPS percentage reduction 
Table 1 shows ROC and quality assurance statistics for assessing 
performance of MGH-HPS percent reduction cutoffs in detecting clinical 
response and recovery. Results showed that 45% reductions optimally 
predicted treatment response (as measured by the K(0.5) statistic), 
with the predictive value of a positive test at 0.90 and predictive value 
of a negative test at 0.79. Recovery from TTM was optimally predicted 
by 55–60% reductions, which showed predictive values of a positive 
test at 0.79 and 0.83 and predictive values of negative tests at 0.86 
and 0.83, respectively. 
Table 1. Signal detection analysis of the prediction of clinical response and 
recovery at increasing Massachusetts General Hospital Hairpulling Scale 
(MGH-HPS) total percent reduction cutoff scores. 
MGH-HPS 
reduction 
(%) 
Sensitivity Specificity Positive 
predictive 
power 
Negative 
predictive 
power 
Efficiency K(0.5) 
Predicting treatment response (based on CGI-I) 
≥5 0.98 0.31 0.70 0.89 0.72 0.33 
≥10 0.95 0.31 0.70 0.80 0.71 0.3 
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MGH-HPS 
reduction 
(%) 
Sensitivity Specificity Positive 
predictive 
power 
Negative 
predictive 
power 
Efficiency K(0.5) 
≥15 0.93 0.39 0.72 0.77 0.72 0.35 
≥20 0.93 0.46 0.74 0.80 0.75 0.43 
≥25 0.91 0.54 0.77 0.78 0.77 0.47 
≥30 0.91 0.62 0.80 0.80 0.80 0.55 
≥35 0.88 0.73 0.84 0.79 0.83 0.62 
≥40 0.88 0.81 0.88 0.81 0.86 0.69 
≥45 0.86 0.85 0.90 0.79 0.86 0.70 
≥50 0.84 0.85 0.90 0.76 0.84 0.67 
≥55 0.70 0.89 0.91 0.64 0.77 0.54 
≥60 0.63 0.92 0.93 0.60 0.74 0.50 
≥65 0.47 0.96 0.95 0.52 0.65 0.37 
≥70 0.35 1 1 0.48 0.59 0.29 
 
Predicting recovery (based on CGI-S) 
≥5 1 0.24 0.52 1 0.58 0.22 
≥10 1 0.26 0.53 1 0.59 0.24 
≥15 1 0.34 0.55 1 0.64 0.32 
≥20 1 0.40 0.57 1 0.67 0.37 
≥25 0.97 0.45 0.59 0.94 0.68 0.39 
≥30 0.97 0.50 0.61 0.95 0.71 0.44 
≥35 0.94 0.58 0.64 0.92 0.74 0.49 
≥40 0.94 0.63 0.67 0.92 0.77 0.55 
≥45 0.94 0.68 0.71 0.93 0.80 0.60 
≥50 0.94 0.71 0.73 0.93 0.81 0.63 
≥55 0.84 0.82 0.79 0.86 0.83 0.65 
≥60 0.77 0.87 0.83 0.83 0.83 0.65 
≥65 0.58 0.92 0.86 0.73 0.77 0.52 
≥70 0.045 0.97 0.93 0.69 0.74 0.45 
3.3. Determining treatment response and recovery 
based on MGH-HPS raw score reduction 
Table 2 shows ROC and quality assurance statistics for assessing 
performance of MGH-HPS point reduction cutoffs in detecting clinical 
response and recovery. These results indicate that a seven-point raw 
score reduction was most efficient at identifying treatment response. 
PPP at the seven-point level was 0.82 while NPP was 0.72. Similarly, 
the seven-point raw score reduction was most efficient at identifying 
recovery, with PPP and NPP at 0.64 and 0.88, respectively. Of note, 
the K(0.5) values reflect agreement that is not as strong as when the 
MGH-HPS percent reductions are used, and the peak K(0.5) value for 
raw score reductions predicting recovery (0.46) is lower than the peak 
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raw score reductions predicting response (0.53). As such, raw score 
reductions, particularly predicting recovery, might not be very efficient 
prediction tools. 
Table 2. Signal detection analysis of the prediction of clinical response and 
recovery at increasing Massachusetts General Hospital Hairpulling Scale 
(MGH-HPS) total raw score cutoff scores. 
MGH-HPS 
reduction 
(%) 
Sensitivity Specificity Positive 
predictive 
power 
Negative 
predictive 
power 
Efficiency K(0.5) 
Predicting treatment response (based on CGI-I) 
≥1 0.98 0.31 0.70 0.89 0.72 0.33 
≥2 0.93 0.35 0.70 0.75 0.71 0.31 
≥3 0.93 0.39 0.71 0.77 0.72 0.35 
≥4 0.88 0.54 0.76 0.74 0.75 0.45 
≥5 0.88 0.54 0.76 0.74 0.75 0.45 
≥6 0.88 0.62 0.79 0.76 0.78 0.52 
≥7 0.84 0.69 0.82 0.72 0.78 0.53 
≥8 0.70 0.77 0.83 0.61 0.72 0.44 
≥9 0.70 0.85 0.88 0.63 0.75 0.51 
≥10 0.61 0.89 0.9 0.58 0.71 0.44 
≥11 0.54 0.89 0.89 0.54 0.66 0.37 
 
Predicting recovery (based on CGI-S) 
≥1 1 0.24 0.52 1 0.58 0.22 
≥2 1 0.32 0.54 1 0.62 0.29 
≥3 1 0.34 0.55 1 0.64 0.32 
≥4 0.94 0.45 0.58 0.90 0.67 0.36 
≥5 0.94 0.45 0.58 0.90 0.67 0.36 
≥6 0.94 0.50 0.60 0.91 0.70 0.42 
≥7 0.90 0.58 0.64 0.88 0.72 0.46 
≥8 0.71 0.63 0.61 0.73 0.67 0.34 
≥9 0.71 0.68 0.65 0.74 0.70 0.39 
≥10 0.61 0.74 0.66 0.74 0.68 0.35 
≥11 0.55 0.76 0.65 0.67 0.67 0.32 
3.4. Determining treatment response and recovery 
based on NIMH-TSS percent reduction 
Table 3 shows ROC and quality assurance statistics for assessing 
performance of NIMH-TSS percent reductions cutoffs in detecting 
treatment response and recovery. Results indicate that a 30–40% 
reduction in scores maximally predict clinical response, with PPP and 
NPP at 0.89 and 0.84 for all percentiles within that range. Recovery 
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from TTM was optimally predicted by a much higher percentile 
reduction, 65%, which showed PPP of 0.96 and NPP of 0.84. 
Table 3. Signal detection analysis of the prediction of clinical response and 
recovery at increasing National Institutes of Mental Health Trichotillomania 
Severity Scale (NIMH-TSS) total percent reduction cutoff scores. 
NIMH-TSS 
reduction 
(%) 
Sensitivity Specificity Positive 
predictive 
power 
Negative 
predictive 
power 
Efficiency K(0.5) 
Predicting treatment response (based on CGI-I) 
≥5 1 0.27 0.69 1 0.72 0.32 
≥10 1 0.42 0.74 1 0.78 0.48 
≥15 0.98 0.50 0.76 0.93 0.80 0.53 
≥20 0.98 0.54 0.78 0.93 0.81 0.56 
≥25 0.93 0.58 0.78 0.83 0.80 0.54 
≥30 0.91 0.81 0.89 0.84 0.87 0.72 
≥35 0.91 0.81 0.89 0.84 0.87 0.72 
≥40 0.91 0.81 0.89 0.84 0.87 0.72 
≥45 0.88 0.81 0.88 0.81 0.86 0.69 
≥50 0.86 0.85 0.90 0.79 0.86 0.70 
≥55 0.72 0.89 0.91 0.67 0.78 0.57 
≥60 0.63 0.96 0.96 0.61 0.75 0.53 
≥65 0.56 0.96 0.96 0.57 0.71 0.46 
≥70 0.42 0.96 0.95 0.50 0.62 0.32 
 
Predicting recovery (based on CGI-S) 
≥5 1 0.18 0.50 1 0.55 0.17 
≥10 1 0.30 0.53 1 0.61 0.27 
≥15 0.97 0.34 0.55 0.93 0.62 0.29 
≥20 0.97 0.37 0.56 0.93 0.64 0.32 
≥25 0.97 0.45 0.59 0.94 0.68 0.39 
≥30 0.97 0.63 0.68 0.96 0.78 0.58 
≥35 0.97 0.63 0.68 0.96 0.78 0.58 
≥40 0.97 0.63 0.68 0.96 0.78 0.58 
≥45 0.94 0.63 0.67 0.92 0.77 0.55 
≥50 0.94 0.68 0.71 0.93 0.80 0.60 
≥55 0.87 0.82 0.79 0.89 0.84 0.68 
≥60 0.81 0.92 0.89 0.85 0.86 0.73 
≥65 0.77 0.97 0.96 0.84 0.88 0.76 
≥70 0.61 1 1 0.76 0.82 0.64 
≥75 0.48 1 1 0.70 0.77 0.51 
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3.5. Determining treatment response and recovery 
based on NIMH-TSS raw score reduction 
Table 4 shows ROC and quality assurance statistics for assessing 
performance of NIMH-TSS raw score reduction cutoffs in detecting 
treatment response and recovery. Results show that a six-point 
reduction on this measure maximally predicts clinical response, with 
PPP and NPP at 0.88 and 0.78, respectively. Similarly, the six-point 
reduction also optimally predicted recovery, with PPP at 0.69 and NPP 
0.93. Of note, the K(0.5) values in this analysis are considerably lower 
than those shown when using the NIMH-TSS percent reductions, 
appearing to behave similarly to the relationship between percent 
reductions and raw cutoffs on the MGH-HPS. 
Table 4. Signal detection analysis of the prediction of clinical response and 
recovery at increasing National Institutes of Mental Health Trichotillomania 
Severity Scale (NIMH-TSS) total point reduction cutoff scores. 
NIMH-TSS 
reduction 
(%) 
Sensitivity Specificity 
Positive 
predictive 
power 
Negative 
predictive 
power 
Efficiency K(0.5) 
Predicting treatment response (based on CGI-I) 
≥1 1 0.27 0.69 1 0.72 0.32 
≥2 0.98 0.46 0.75 0.92 0.78 0.49 
≥3 0.98 0.50 0.76 0.93 0.80 0.53 
≥4 0.93 0.62 0.80 0.84 0.81 0.58 
≥5 0.88 0.73 0.84 0.79 0.83 0.62 
≥6 0.86 0.81 0.88 0.78 0.84 0.66 
≥7 0.77 0.81 0.87 0.68 0.78 0.55 
≥8 0.70 0.81 0.86 0.62 0.74 0.48 
≥9 0.61 0.85 0.87 0.56 0.70 0.41 
≥10 0.42 0.92 0.90 0.49 0.61 0.29 
≥11 0.33 0.92 0.88 0.45 0.55 0.21 
 
Predicting recovery (based on CGI-S) 
≥1 1 0.18 0.5 1 0.55 0.17 
≥2 0.97 0.32 0.54 0.92 0.61 0.26 
≥3 0.97 0.34 0.55 0.93 0.62 0.29 
≥4 0.97 0.47 0.6 0.95 0.7 0.42 
≥5 0.94 0.58 0.64 0.92 0.74 0.49 
≥6 0.94 0.66 0.69 0.93 0.78 0.58 
≥7 0.84 0.68 0.68 0.84 0.75 0.51 
≥8 0.74 0.68 0.66 0.77 0.71 0.42 
≥9 0.68 0.76 0.7 0.74 0.72 0.44 
≥10 0.48 0.87 0.75 0.67 0.7 0.36 
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NIMH-TSS 
reduction 
(%) 
Sensitivity Specificity 
Positive 
predictive 
power 
Negative 
predictive 
power 
Efficiency K(0.5) 
≥11 0.42 0.92 0.81 0.66 0.7 0.36 
4. Discussion 
The purpose of this investigation was to identify maximally 
efficient cutoff levels of two widely used measures of TTM severity. For 
predicting treatment response, the most efficient reductions on the 
MGH-HPS were found to be 45% or seven-point reductions, and the 
most efficient reductions on the NIMH-TSS were found to be 30–40% 
or six-points. For predicting recovery from TTM, the most efficient 
reductions on the MGH-HPS were found to be 55–60% or seven-point 
reductions, and the most efficient reductions on the NIMH-TSS were 
found to be 65% or six-points. We offer these empirically derived 
cutoffs so that future researchers and clinicians might utilize them to 
maximize their predictive validity in labeling TTM patients as clinically 
significant treatment responders. Likewise, researchers who develop 
clinical trials using these outcome measures should power their studies 
to ensure that these clinically meaningful effect sizes can be detected. 
It might be expected that the degree of score reduction needed 
to achieve response might be less than that needed to achieve 
recovery from TTM. However, results showed that while percentage 
reductions where higher when predicting recovery than when 
predicting response, the raw score cutoffs did not change. This result 
might be explained by several factors. When the CGI-I is rated, trained 
evaluators consider the degree of change shown by the individual with 
reference to their baseline disorder severity. Conversely, the CGI-S 
ratings are static categories of TTM severity. An individual who enters 
treatment in the severe range of severity but exits treatment in the 
moderate range could be seen as having the same degree of 
improvement as an individual who enters treatment in the moderate 
range and exits in the mild, or undiagnosed, range. However, 
achieving recovery requires a greater degree of change for those who 
start treatment in the severe range as compared to those who start in 
the moderate range, meaning that individuals in the latter group are 
more likely to achieve recovery than those in the former group. For 
example, an MGH-HPS reduction from 12 to 5 conveys a very different 
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clinical picture than one from 26 to 19. Both are 7-point reductions, 
but the former would be considered to have significantly improved and 
recovered while the latter has just significantly improved. If we were 
instead measuring the same two hypothetical individuals’ response by 
percent reduction, the first would constitute a 58% reduction while the 
second would only represent a reduction of 27%. As such, the 
relatively high percent changes but small raw score change shown by 
those who recover from moderately severe pulling would be over-
represented in those who recover from TTM and cause the difference 
in percentile reductions seen between predictions of response and 
recovery. 
The same problem could have also conversely influenced the 
finding that the efficiency of both measures was notably higher when 
using percent reductions rather than raw score reductions. Indeed, 
while floor effects do bias the interpretation of percent reductions as 
predicting response versus recovery, they do provide an index of the 
degree of change relative to baseline levels. Raw score differences 
contain no information about baseline disorder severity, and thus 
might be less efficient at predicting criterion indices of treatment 
response and recovery. Still, additional factors might also influence the 
effectiveness of both raw score and percent reductions in predicting 
treatment response and recovery from TTM, such as regression toward 
the mean. With these scaling limitations in mind, clinicians should 
consider both raw score and percent reductions when determining 
whether a particular client has significantly responded to treatment or 
recovered from TTM. Researchers should also consider which criterion 
of improvement is most important to use when powering a study, as 
judgments of treatment efficacy could be expected to significantly vary 
depending on this question (Nelson et al., 2014). 
This study identified the most optimal cutoffs based on their 
agreement with a criterion outcome measure, but the cutoff 
percentages and score reductions surrounding the most optimal cutoffs 
did not drop off steeply. This suggests that the incremental efficiency 
of this study's proposed cutoffs relative to nearby cutoffs is low, and 
other studies might find similar but not exact replications. In order to 
determine if these cutoffs generalize to other samples, multiple 
replications are required. It is also important that the cutoffs 
recommended in the current study be placed into clinical context. Hair 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Anxiety Disorders, Vol 36 (December 2015): pg. 44-51. DOI. This article is © Elsevier and permission has been 
granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article to be 
further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
19 
 
pulling is a constantly fluctuating behavior, and scores on the MGH-
HPS and NIMH-TSS can vary over the passage of time. Our analyses 
indicated that certain raw score and percentage reductions could best 
identify persons who responded to treatment, but clinicians who treat 
TTM should consider these cutoffs alongside other clinical data. 
In addition to the cutoff scores generated, the study had a 
number of methodological strengths, including a relatively large 
sample (for a disorder of low prevalence), administration of multiple 
treatments, and the use of multiple measures with separate response 
formats. Furthermore, we examined two widely used measures of TTM 
symptom severity, one being self-report and the other clinician-
administered. Results of this analysis are thus applicable in a variety of 
assessment contexts, whether one wishes to use only one method or 
collect multiple sources of information. 
The study had several limitations. First, the analysis could have 
been strengthened through the inclusion of additional therapeutic 
conditions, such as pharmacotherapy. Given that meta-analyses have 
consistently shown that drug treatments of TTM are less effective than 
behavioral treatments (Bloch et al., 2007 and McGuire et al., 2014), 
this might be considered a minor limitation. Second, the findings could 
have been enhanced by an analysis of moderating variables, such as 
gender or age. It is possible that such factors might predict different 
degrees of symptom reduction necessary for clinical response. 
However, the sample was heavily biased towards females (89.85%), 
as is common in treatment trials of TTM (Christenson, Mackenzie, & 
Mitchell, 1994). The highly unequal cell sizes would have made such 
analyses inappropriate for gender. Third, adults were the only age 
group studied in this intervention, and clinically significant symptom 
reductions might be different in children and adolescents. Comparable 
analyses within pediatric populations are needed to examine the 
generalizability of these cutoffs for all age groups. 
Despite these limitations, the current study represents the first 
effort at quantifying clinically significant dimensional reductions in hair 
pulling severity. Given that the MGH-HPS and NIMH-TSS are widely 
used in TTM research and treatment, researchers and providers can 
make use of the guidelines for assessing treatment response outlined 
in this study. 
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